These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 32362513)

  • 1. Statin utilization and low-density lipoprotein cholesterol in statin-treated patients with atherosclerotic cardiovascular disease: Trends from a community-based health care delivery system, 2002-2016.
    Romanelli RJ; Ito MK; Karalis DG; Huang HC; Iorga ŞR; Kam IW; Thompson S; Azar KMJ
    J Clin Lipidol; 2020; 14(3):305-314. PubMed ID: 32362513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trends in high-intensity statin use and low-density lipoprotein cholesterol control among patients enrolled in a clinical pharmacy cardiac risk service.
    Lamprecht DG; Shaw PB; King JB; Hogan KN; Olson KL
    J Clin Lipidol; 2018; 12(4):999-1007. PubMed ID: 29803357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of 2013 ACC/AHA Blood Cholesterol Guidelines on Statin Treatment Patterns and Low-Density Lipoprotein Cholesterol in Atherosclerotic Cardiovascular Disease Patients.
    Okerson T; Patel J; DiMario S; Burton T; Seare J; Harrison DJ
    J Am Heart Assoc; 2017 Mar; 6(3):. PubMed ID: 28314797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical characteristics and treatment patterns in patients with atherosclerotic cardiovascular disease with hypercholesterolemia: a retrospective analysis of a large US real-world database cohort.
    Lahoz R; Seshagiri D; Electricwala B; Achouba A; Ding Y; Heo JH; Cristino J; Studer R
    Curr Med Res Opin; 2024 Jan; 40(1):15-25. PubMed ID: 37941428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease.
    Chan J; Rajalingam T; Fossella J; Zhou H; Eisenberg N; Roche-Nagle G
    Ann Vasc Surg; 2020 Nov; 69():197-205. PubMed ID: 32554202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
    Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
    JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid-Lowering Therapy and Low-Density Lipoprotein Cholesterol (LDL-C) Goal Achievement in High-Cardiovascular-Risk Patients in Fuzhou, China.
    Wang X; He Y; Wang T; Li C; Ma Z; Zhang H; Ma H; Zhao H
    J Cardiovasc Pharmacol Ther; 2020 Jul; 25(4):307-315. PubMed ID: 31918567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for Health and Care Excellence (NICE) 2014 lipid modification guidelines.
    Steen DL; Khan I; Ansell D; Sanchez RJ; Ray KK
    BMJ Open; 2017 Feb; 7(2):e013255. PubMed ID: 28213597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relation of Cardiovascular Events and Deaths to Low-Density Lipoprotein Cholesterol Level Among Statin-Treated Patients With Atherosclerotic Cardiovascular Disease.
    Chamberlain AM; Cohen SS; Weston SA; Fox KM; Xiang P; Killian JM; Qian Y
    Am J Cardiol; 2019 Jun; 123(11):1739-1744. PubMed ID: 30948001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Low-Density Lipoprotein Testing After an Atherosclerotic Cardiovascular Event with Subsequent Statin Adherence and Intensification.
    Rana JS; Virani SS; Moffet HH; Liu JY; Coghlan LA; Vasadia J; Ballantyne CM; Karter AJ
    Am J Med; 2022 May; 135(5):603-606. PubMed ID: 34861203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
    Rosenblit PD
    Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The low-density lipoprotein cholesterol lowering is an ineffective surrogate marker of statin responsiveness to predict cardiovascular outcomes: The 10-year experience of matched population (a STROBE-compliant article).
    Hyun MH; Jang JW; Choi BG; Na JO; Choi CU; Kim JW; Kim EJ; Rha SW; Park CG; Lee E; Seo HS
    Medicine (Baltimore); 2019 Dec; 98(51):e18510. PubMed ID: 31861037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. To what extent do high-intensity statins reduce low-density lipoprotein cholesterol in each of the four statin benefit groups identified by the 2013 American College of Cardiology/American Heart Association guidelines? A VOYAGER meta-analysis.
    Karlson BW; Palmer MK; Nicholls SJ; Lundman P; Barter PJ
    Atherosclerosis; 2015 Aug; 241(2):450-4. PubMed ID: 26074319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-density lipoprotein cholesterol response after statin initiation among persons living with human immunodeficiency virus.
    Burkholder GA; Muntner P; Zhao H; Mugavero MJ; Overton ET; Kilgore M; Drozd DR; Crane HM; Moore RD; Mathews WC; Geng E; Boswell S; Floris-Moore M; Rosenson RS
    J Clin Lipidol; 2018; 12(4):988-998.e5. PubMed ID: 29853312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guidelines impact cholesterol management.
    Yu S; Zolfaghari K; Rascati KL; Copeland LA; Godley PJ; McNeal C
    J Clin Lipidol; 2019; 13(3):432-442. PubMed ID: 30992244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins.
    Fox KM; Tai MH; Kostev K; Hatz M; Qian Y; Laufs U
    Clin Res Cardiol; 2018 May; 107(5):380-388. PubMed ID: 29273856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temporal changes in statin prescription and intensity at discharge and impact on outcomes in patients with newly diagnosed atherosclerotic cardiovascular disease-Real-world experience within a large integrated health care system: The IMPRES study.
    Anderson JL; Knowlton KU; May HT; Bair TL; Armstrong SO; Lappé DL; Muhlestein JB
    J Clin Lipidol; 2018; 12(4):1008-1018.e1. PubMed ID: 29703626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.
    Giugliano RP; Keech A; Murphy SA; Huber K; Tokgozoglu SL; Lewis BS; Ferreira J; Pineda AL; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
    JAMA Cardiol; 2017 Dec; 2(12):1385-1391. PubMed ID: 29117276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gaps in Guideline-Based Lipid-Lowering Therapy for Secondary Prevention in the United States: A Retrospective Cohort Study of 322 153 Patients.
    Navar AM; Kolkailah AA; Gupta A; Gillard KK; Israel MK; Wang Y; Peterson ED
    Circ Cardiovasc Qual Outcomes; 2023 Aug; 16(8):533-543. PubMed ID: 37529931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between persistence with statin therapy and reduction in low-density lipoprotein cholesterol level: analysis of real-life data from community settings.
    Shalev V; Goldshtein I; Halpern Y; Chodick G
    Pharmacotherapy; 2014 Jan; 34(1):1-8. PubMed ID: 23836549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.